Contribution of FDG-PET on staging and management of NSCLC planned for concomitant chemoradiotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 664s Year: 2007
Chemotherapy plus resection is not better than chemoradiotherapy for baseline unresectable stage IIIA-N2 NSCLC Source: ISSN=ISSN 1810-6838, ISBN=, page=380 Year: 2007
Induction chemotherapy and simultaneous radiochemotherapy or radiotherapy in inoperable NSCLC (stage IIIA/IIIB) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005
FDG-PET is superior to conventional CT in predicting histologic responses after induction therapy for locally advanced NSCLC Source: Annual Congress 2010 - Staging of lung cancer Year: 2010
Indcution chemotherapy and radiotherapy vs. induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97 Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97 Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004
Accuracy of re-mediastinoscopy and fusion PET-CT in the assessment of lymph node (LN) downstaging after induction chemotherapy for N2 non-small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 602s Year: 2006
Prospective evaluation of repeat integrated PET/CT scan after induction therapy for stage IIIA-N2 lung cancer Source: ISSN=ISSN 1810-6838, ISBN=, page=186 Year: 2006
Comparative evaluation of resectability, postoperative morbidity and mediastinal downstaging after cisplatin-based chemoinduction versus radiochemoinduction for stage III non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 214s Year: 2003
Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Staging and restaging in the era of multimodality treatment Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Stage IIIA/B NSCLC: long-term results of induction chemotherapy and surgery Source: ISSN=ISSN 1810-6838, ISBN=, page=279 Year: 2008
Long-term follow-up comparing postoperative chemotherapy or radiotherapy and surgery with surgery alone in resectable nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 131s Year: 2001
The comparison of the findings of preoperative PET-CT and surgical pathology in patients with non-small cell lung cancer those with and without induction therapy Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
N-staging in CT N0 -N1 non-small cell lung cancer patients: is there any place for mediastinoscopy? Source: Annual Congress 2007 - Staging, diagnostic procedures and complex situations in thoracic surgery Year: 2007
Clinical value of 18-FDG PET-CT in mediastinal lymph node staging in non-small cell lung cancer (NSCLC) patients with previous cN0-1 on CT Source: Annual Congress 2007 - Diagnosis of thoracic malignancies Year: 2007
Concurrent WBBS and FDG-PET and primary staging of NSCLC, a retrospective analysis Source: Annual Congress 2009 - Chest imaging in evolution: new techniques and new possibilities Year: 2009